RS BioTherapeutics, which recently announced positive results from a proof of concept study of its RSBT-001 semi-synthetic cannabidiolic acid (CBDa) in a mouse model, said that the company has raised $3 million in a Seed II funding round. The company says that it is partnered with Synthonics and Marshall University on development of a nebulized formulation of RSBT-001 for the treatment of lung inflammation due to pulmonary diseases such as asthma, CDOP, COVID-19, ARDS, and cystic fibrosis.
RS BioTherapeutics Chief Strategy Officer Justin Molignoni commented, “Closing this round of funding is an exciting milestone which will help accelerate the growth of the company. These funds will not only support our growing organization but also our development of RSBT-001 as we work towards an IND submission.”
Read the RS BioTherapeutics press release.
